Earnings call transcript: CTS tops Q3 2026 estimates and raises outlook

CTS beat Q3 2026 estimates with adjusted EPS of $0.77 versus $0.67 consensus and revenue of $149.6 million versus about $146 million; gross margin reached a record 42.2%, up 330 basis points year over year. The company raised 2026 guidance to sales of $580–$590 million and adjusted EPS of $2.78–$2.88, while noting margins may normalize from Q3 levels. Shares rose 5.42% to $56.84 in premarket trading. The Millar acquisition is expected to add about $30 million in annual revenue, with EPS accretion expected in the second half of 2027.

Analysis

The beat looks higher-quality on operating execution, but less repeatable than headline EPS implies: management attributed about $0.04 of quarterly EPS to FX, while unusually favorable project mix also lifted gross margin. Normalize those benefits and the next-quarter comparison may disappoint even if underlying demand remains sound. Demand is not equally broad: industrial and A&D bookings support the near-term outlook, but medical’s 0.66 book-to-bill is a watch item against its strong reported growth. A&D’s 1.91 ratio is constructive but lumpy, not a straight-line growth signal.

Millar adds a useful medical-sensing platform, but near-term EPS is not the thesis: EBITDA may initially be less than margin-accretive, and stated EPS accretion is not expected until 2H27. The cash purchase also reduces financial flexibility relative to the pre-deal balance sheet; verify post-close cash and integration disclosures before underwriting further buybacks or acquisitions. Longer term, success depends on converting design wins and cross-selling into recurring growth, not simply adding acquired revenue.

The 5.4% premarket gain risks pricing in a clean continuation of record profitability. With margin normalization explicitly flagged and a trailing P/E of 23.7x in the supplied data, the contrarian risk is multiple compression on merely good—not record—execution. No strong basis to chase the opening move; the next 1–3 months hinge on Q4 guidance delivery and order conversion, while Millar’s growth contribution is a 6–18-month test.

Key Decisions for Investors

• Avoid chasing the premarket gap. Consider a staged CTS long only after the initial reaction settles, contingent on Q4 sales tracking the raised outlook and gross-margin decline remaining consistent with management’s normalization warning.
• For a relative-value expression, pair a modest CTS long with a broad industrial-sector short rather than taking an outright momentum position; thesis is diversified-end-market execution, with risk controlled if CTS underperforms the sector after results.
• Track medical book-to-bill, A&D backlog conversion, and quarterly gross margin separately. A sustained medical book-to-bill below 1 or a sharper-than-signaled margin drop would weaken the growth-quality thesis and argue for reducing exposure.
• Reassess after the next earnings report: falsifiers include a guidance cut, weak conversion of A&D bookings into revenue, or Millar integration costs delaying the stated 2H27 EPS-accretion path. Verify post-acquisition cash, customer concentration, and Millar standalone growth before assigning further acquisition value.